New 52-week high$29.21+0.7% vs prior high · 2026-09-02
Pfizer hit a fresh 52-week high at $29.21, topping its September 2 peak. The drugmaker is now trading at levels no buyer from the past year is underwater on.
Latest Activity
5stocks hit new 52-week highs this week
- DELLDell Technologies$524.14+6.0%
- SNOWSnowflake$337.18+5.7%
- BOXBox$35.19+3.5%
- PFEPfizer$28.45+1.6%
- CVXChevron$208.6+1.2%
Five stocks cleared 52-week highs this week: Dell topped its prior peak by 6% at $524.14, with Snowflake close behind at 5.7%. Box, Pfizer and Chevron rounded out the list with narrower breakouts.
New 52-week high$29.02+1.6% vs prior high · 2026-08-25
Pfizer just marked a fresh 52-week high at $29.02, 1.58% above the peak it set on Aug. 25. Anyone anchored to the low-$23 range from a year ago is now looking at a very different reference point.
7stocks hit new 52-week highs this week
- BOXBox$34.98+4.0%
- FTNTFortinet$166+2.7%
- ABNBAirbnb$189.43+2.2%
- EXPEExpedia$329.44+1.9%
- RBRKRubrik$93.05+1.8%
- KOCoca-Cola$89.66+1.6%
- PFEPfizer$27.96+1.2%
Seven names printed fresh 52-week highs this week, spanning travel, software and defensives. Box led with a 3.98% clearance over its prior peak, with Coca-Cola, Pfizer, Airbnb and Expedia also at new records.
6stocks hit new 52-week highs this week
- SSentinelOne$20.94+6.1%
- KOCoca-Cola$91.1+2.3%
- EXPEExpedia$321.63+1.3%
- ABNBAirbnb$187.3+1.2%
- ABBVAbbVie$264.96+1.0%
- PFEPfizer$28.07+0.6%
Six names hit fresh 52-week highs this week: SentinelOne led at 6.14% above its prior peak, with Coca-Cola, Expedia, Airbnb, AbbVie and Pfizer all clearing old ceilings too.
New 52-week high$28.24+0.6% vs prior high · 2026-04-01
Pfizer closed at $28.24, a new 52-week high that clears the April 1 peak. The drugmaker has now taken out the ceiling that capped it all spring, making that old level the line to defend.
PFE Coverage
10:12am ET
ETF
Morningstar’s Dividend ETF Is Kind of Perfect for Retirees Right Now
A retiree living off a portfolio needs income that keeps coming. The First Trust Morningstar Dividend Leaders Index Fund (NYSEARCA:FDL) has paid distributions four times a year since 2006. FDL tracks Morningstar’s…
10:04am ET
Personal Finance
How to Build $9,050 a Month in Dividend Income Without Selling a Single Share
The capital required to collect over $108,000 a year in dividends without selling a share swings by more than $2 million depending on one decision you make before buying anything.
7:50am ET
Investing
5 Large-Cap Giants Paying 5% and Bigger Dividends to Be Bought and Held Forever
Four of these five large-cap dividend stocks just dropped sharply, pushing their yields above 6%, but a rising yield can signal opportunity or a warning sign depending on what sits beneath the…
7:15am ET
Investing
J&J Beat and Raised. The Stock Fell Anyway. Here’s What the Target Says
Johnson and Johnson crushed earnings, raised guidance, and still watched its stock crater nearly 6% in a single session. Understanding what spooked investors reveals whether Tuesday's selloff is a trap or a…
11:48am ET
Investing
Johnson & Johnson Drops 5% as One-Time Charges Overshadow Raised Full-Year Outlook; Eli Lilly Dips, Pfizer Sits Out the Selloff
Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) stock is at $249.55, down 5% early in the session. The company raised its full-year outlook in the same release that showed its reported…
9:41am ET
Investing
A $750,000 Roth IRA Portfolio Loaded With These Dividend Stocks Pays $47,800 a Year and the IRS Gets None of It
Six high-yield dividend stocks can quietly hand the IRS thousands of dollars every single year, but where you hold them changes everything. The bracket you sit in determines exactly how much you…
9:15am ET
Investing
These 6 Dividend Stocks Look Like Income Bargains. Their Payout Ratios Say Otherwise
Six stocks are flashing high yields that look like income bargains, but a closer look at their payout ratios tells a very different story about which ones can actually keep the checks…
9:50am ET
Investing
Every Roth IRA Needs These High-Yield Dividend Stocks Over 6%
Holding high-yield dividend stocks outside a Roth quietly drains thousands of dollars every year, and the losses compound in a way most investors never calculate until it is too late.
9:15am ET
Investing
4 Blue Chip Giants That May Have to Cut Their Dividends
Four household names are paying dividend yields above 5%, but their earnings, cash flow, and balance sheets tell a different story than their press releases. Before you count on those checks arriving,…
9:00am ET
Investing
These 4 Dividend Stocks Offer Tempting Yields. But the Warning Signs Are Getting Harder to Ignore
Kraft Heinz, Pfizer, Verizon, and Dow all flash yields above 4%, but behind each payout sits a mix of impairments, rising debt, and shrinking sales that could turn a tempting income stream…
10:00am ET
Investing
How Much More Dividend Income a Roth IRA Keeps on a Half-Million-Dollar Portfolio
Six dividend stocks in a $500,000 portfolio sound like a solid income plan, but where you hold them decides how much of that income you actually keep, and the difference compounds into…
9:00am ET
Investing
CDs vs. Dividend Stocks: The Income Gap Could Be Bigger Than Retirees Think
Retirees chasing income face a choice that looks simple on paper but hides a tax trap, a reinvestment problem, and a dividend cut risk that most income comparisons never mention.
7:59am ET
Personal Finance
$12,300 a Month in Dividends and Not One Bond: Is This Portfolio Too Good to Be True?
A portfolio built entirely around stocks and equity funds can generate $12,300 a month, or $147,600 a year, in income. The no-bond design stands out with the 10-year Treasury yielding 5.2%. Using…
1:45pm ET
Investing
Pfizer’s Dividend Yield Is Above 6%. Wall Street May Be Sending a Warning
Pfizer's dividend yield has climbed well above what most blue-chip drugmakers offer, and the reason behind that gap matters far more than the number itself.
11:48am ET
Investing
Moderna Climbs 5% on NASDAQ 100 Entry; Pfizer Inches Higher, BioNTech Ticks Up
Moderna (NASDAQ:MRNA | MRNA Price Prediction) stock trades at $207.80, up 5%, after its addition to the NASDAQ 100 took effect. That entry places a company once valued as a COVID-19 vaccine…